文献速递颈动脉与弓上血管

经颈动脉血运重建与经股动脉颈动脉支架置入的解剖学适用性

Anatomic eligibility for transcarotid artery revascularization and transfemoral carotid artery stenting.
PubMed 文献 · J Vasc Surg · 2019-03-08

该回顾性研究分析了2012至2015年间118例患者共236条颈动脉,评估基于解剖标准对经颈动脉血运重建(TCAR)的适用性,以及高解剖风险经股动脉颈动脉支架置入(tfCAS)者中可接受TCAR的比例。结果显示224条非闭塞颈动脉中72%符合TCAR适应证,而高tfCAS风险动脉中69%适合TCAR。

要点

  • 多数拟行血运重建的颈动脉符合TCAR解剖标准,可作为可行治疗选择。
  • 高tfCAS解剖风险的颈动脉中约69%仍适合TCAR。
  • 高龄、高脂血症和COPD与TCAR不符合独立相关。

核心结论

  • 多数拟行血运重建患者的颈动脉符合TCAR解剖适应证。
  • 高tfCAS解剖风险的颈动脉中69%可接受TCAR。

研究设计与样本

  • 回顾性队列研究,纳入2012至2015年连续接受颈动脉内膜剥脱术或支架置入的患者。
  • 排除术后6个月内未行颈部CTA者,最终分析118例患者236条颈动脉。

主要发现

  • 224条非闭塞颈动脉中72%符合TCAR的IFU标准。
  • 100%颈动脉满足ICA直径4-9 mm,100%满足CCA直径≥6 mm,75%满足锁骨至分叉距离≥5 cm,96%无显著CCA穿刺点斑块。
  • 7%颈动脉分叉解剖不适合支架置入,故全队列中68%适合TCAR。
  • 高脂血症(OR 6.7,95%CI 1.7-26,P<.01)、COPD(OR 3.5,95%CI 1.5-8.3,P<.01)和年龄较大(OR 1.1,95%CI 1.0-1.1,P<.01)与TCAR不符合独立相关。
  • 白色人种(OR 0.2,95%CI 0.0-1.0,P=.048)和β受体阻滞剂使用(OR 0.3,95%CI 0.1-0.7,P<.01)与TCAR符合独立相关。

关键数值与推荐

  • TCAR适用标准基于ENROUTE Transcarotid Neuroprotection System的说明书:ICA直径4-9 mm,CCA直径≥6 mm,锁骨至颈动脉分叉距离≥5 cm,CCA穿刺点无显著斑块。

临床怎么用

  • 评估颈动脉血运重建时,应基于CTA解剖特征判断TCAR适用性。
  • 对高tfCAS解剖风险患者,可考虑TCAR作为替代方案。

局限性

  • 回顾性设计,样本量有限。
  • 未报告临床结局,仅评估解剖适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Transcarotid artery revascularization (TCAR) has emerged as an alternative to transfemoral carotid artery stenting (tfCAS). We investigated the proportion of carotid arteries undergoing revascularization procedures that would be eligible for TCAR based on anatomic criteria and how many arteries at high anatomic risk for tfCAS would be amenable to TCAR. METHODS: We performed a retrospective review of consecutive patients who underwent carotid endarterectomy or carotid stenting between 2012 and 2015. Patients were excluded if computed tomography angiography of the neck was not performed within 6 months of the procedure. We assessed TCAR eligibility on the basis of the instructions for use of the ENROUTE Transcarotid Neuroprotection System (Silk Road Medical, Sunnyvale, Calif) and high anatomic risk for tfCAS on the basis of anatomic factors known to make carotid cannulation more difficult or hazardous. RESULTS: Of the 118 patients and 236 carotid arteries identified, 12 carotid arteries were excluded for presence of an occluded internal carotid artery (ICA). Of the remaining 224 carotid arteries, 72% were eligible for TCAR on the basis of the instructions for use criteria; 100% had 4- to 9-mm ICA diameters, 100% had ≥6-mm common carotid artery (CCA) diameter, 75% had ≥5-cm clavicle to carotid bifurcation distance, and 96% lacked significant CCA puncture site plaque. In addition, 7% of carotid arteries had bifurcation anatomy unfavorable for stenting; thus, of the entire cohort of arteries examined, 68% were eligible for TCAR. Hyperlipidemia (odds ratio [OR], 6.7; 95% confidence interval [CI], 1.7-26; P < .01), chronic obstructive pulmonary disease (OR, 3.5; 95% CI, 1.5-8.3; P < .01), and older age (OR, 1.1; 95% CI, 1.0-1.1; P < .01) were independently associated with TCAR ineligibility, whereas white race (OR, 0.2; 95% CI, 0.0-1.0; P = .048) and beta-blocker use (OR, 0.3; 95% CI, 0.1-0.7; P < .01) were independently associated with TCAR eligibility. In addition, 24% of carotid arteries were considered to be at high risk for tfCAS for the presence of a type III aortic arch (7.6%), severe aortic calcification (3.3%), tandem CCA lesions (7.1%), moderate to severe stenosis at the carotid ostium (8.9%), and tortuous distal ICA precluding embolic filter placement (4.5%). Active smoking (OR, 4.4; 95% CI, 1.9-10; P < .01), hyperlipidemia (OR, 4.0; 95% CI, 1.2-14; P = .03), and older age (OR, 1.1; 95% CI, 1.0-1.1; P = .02) were independently associated with tfCAS ineligibility, whereas preoperative aspirin (OR, 0.1; 95% CI, 0.0-0.4; P < .001) or clopidogrel (OR, 0.3; 95% CI, 0.1-0.8; P = .01) use was associated with tfCAS eligibility. Of the arteries that were considered to be at high risk for tfCAS, 69% were eligible for TCAR. CONCLUSIONS: The majority of carotid arteries in individuals selected for revascularization meet TCAR eligibility, making TCAR a viable treatment option for many patients.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Wu WW, Liang P, O'Donnell TFX, et al. Anatomic eligibility for transcarotid artery revascularization and transfemoral carotid artery stenting. J Vasc Surg. 2019. PMID: 30853384. doi:10.1016/j.jvs.2018.11.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。